Search Results - Lu Si

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma by Qian Zhao, Teng Wang, Huanhuan Wang, Cheng Cui, Wen Zhong, Diyi Fu, Wanlin Xi, Lu Si, Jun Guo, Ying Cheng, Hongqi Tian, Pei Hu

Connect to this object online.

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies by Hui Tian, Xuan Wang, Bin Lian, Xieqiao Yan, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Siming Li, Li Zhou, Chuanliang Cui, Jun Guo

Connect to this object online.

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study by Yu Du, Zhonghui Qi, Xianbin Liang, Jie Dai, Xiaoting Wei, Xue Bai, Lili Mao, Zhihong Chi, Chuanliang Cui, Bin Lian, Bixia Tang, Xuan Wang, Yu Chen, Jun Guo, Lu Si

Connect to this object online.

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyCapsule Summary by Xue Bai, MD, Aleigha R. Lawless, BS, Juliane A. Czapla, MS, Stefanie C. Gerstberger, MD, PhD, Benjamin C. Park, MD, Seungyeon Jung, BA, Rebecca Johnson, MN, Naoya Yamazaki, MD, PhD, Dai Ogata, MD, PhD, Yoshiyasu Umeda, MD, Caili Li, MB, Jun Guo, MD, PhD, Keith T. Flaherty, MD, Yasuhiro Nakamura, MD, PhD, Kenjiro Namikawa, MD, PhD, Georgina V. Long, MBBS, PhD, Alexander M. Menzies, MBBS, PhD, Douglas B. Johnson, MD, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Lu Si, MD

Connect to this object online.